• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Revlon Climbs, Singing Machine Moves Up And Weber Makes Big Move: 5 Short Squeeze Stocks That May Soar This Week

    8/22/22 11:16:52 AM ET
    $CMRA
    $EMBK
    $GLSI
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $CMRA alert in real time by email

    Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move.

    A short squeeze can occur when a heavily shorted stock rises in value instead of falling. Short sellers could be looking to close out their position and can face a loss if they have to buy back the shares they initially borrowed at a higher price.

    A squeeze can occur when short sellers are forced into buying to cover their position, which can cause shares to move up on many occasions.

    Fintel Data, which requires a subscription, provides a look at several of the top shorted stocks and how likely a short squeeze is to occur.

    Here’s a look at the top five short squeeze candidates for the week of Aug. 22.

    Singing Machine Company: Karaoke audio equipment company The Singing Machine Company (NASDAQ:MICS) tops the short squeeze leaderboard, a position it previously topped in July. The company ranked third in last week’s report. Fintel data shows 26.7% of the float short and a cost to borrow of 100.9%.

    Revlon Inc: Cosmetics company Revlon Inc (NYSE:REV) jumps 27 places on the leaderboard to second place. The company, which declared bankruptcy in June, has been a popular stock for retail traders and also attracted heavy short interest due to bankruptcy and credit concerns. Data shows 36.6% of the float short and a cost to borrow of 101.8%.

    U.S. Well Services: Oil company U.S. Well Services (NASDAQ:USWS) falls one position to third place from last week’s short squeeze leaderboard. The stock moved up 425 positions previously. Data shows 46.9% of the float short, down from last week’s 51.4%. The cost to borrow shares is 16.6%, down from last week’s 20.4%.

    Hour Loop: E-commerce company Hour Loop Inc (NASDAQ:HOUR) moves up one position to fourth place on the leaderboard, with multiple consecutive weeks in the top five. Data shows 17.5% of the float short, in line with last week’s report. The cost to borrow shares is 55.2%, down from last week’s 57.6%.

    Greenwich LifeSciences: Clinical stage biopharmaceutical company Greenwich Lifesciences Inc (NASDAQ:GLSI) moves up 27 positions to rank fifth for the week. Data shows 31.7% of the float short and a cost to borrow of 11.6%.

    Related Link: Bed Bath & Beyond Is Done, What's The Next Meme Stock? This Former Hedge Funder Has One Idea 

    5 Stocks to Watch: Outdoor cooking company Weber Inc (NYSE:WEBR) ranks seventh in the latest short squeeze leaderboard, moving up 49 positions. Data shows 55.2% of the float short and a cost to borrow of 43%. The company has been singled out as one of the potential short squeeze plays by a former hedge fund manager and seen increased discussions on social media.

    Clinical stage biopharmaceutical company HilleVax (NASDAQ:HLVX) moved up 309 positions to ninth place on the leaderboard, one of the biggest increases. Data shows 7.2% of the float short and a cost to borrow of 17.4%.

    Indonesia Energy Corp (NYSE:INDO) has previously been in the top five of the short squeeze leaderboard and could return soon. The oil exploration company has 12.7% of its float short and a cost to borrow of 138.1%.

    Self-driving truck technology company Embark Technology (NASDAQ:EMBK) moved up 3,999 positions on the leaderboard to 15th place. Data shows 29.2% of the float short and a cost to borrow of 7.9%. The company recently had a 1-for-20 reverse stock split.

    Pre-clinical biotechnology company Comera Life Sciences Holdings (NASDAQ:CMRA) moves up 21 places to 16th place on the leaderboard. The stock has one of the highest cost to borrows at 201.3%. Data shows 12.1% of the float short as well.

    Photo via Shutterstock. 

    Get the next $CMRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMRA
    $EMBK
    $GLSI
    $HLVX

    CompanyDatePrice TargetRatingAnalyst
    Greenwich LifeSciences Inc.
    $GLSI
    8/20/2025$45.00Outperform
    Noble Capital Markets
    HilleVax Inc.
    $HLVX
    7/9/2024$28.00 → $2.00Outperform → Market Perform
    Leerink Partners
    HilleVax Inc.
    $HLVX
    7/9/2024$34.00 → $3.00Buy → Hold
    Stifel
    HilleVax Inc.
    $HLVX
    7/9/2024$28.00 → $2.00Buy → Neutral
    H.C. Wainwright
    HilleVax Inc.
    $HLVX
    7/8/2024Buy → Neutral
    Guggenheim
    HilleVax Inc.
    $HLVX
    7/8/2024$24.00 → $5.00Overweight → Neutral
    JP Morgan
    HilleVax Inc.
    $HLVX
    12/13/2023$28.00Buy
    H.C. Wainwright
    Weber Inc.
    $WEBR
    12/13/2022$8.05Sell → Neutral
    Citigroup
    More analyst ratings

    $CMRA
    $EMBK
    $GLSI
    $HLVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

    Issued on behalf of Oncolytics Biotech Inc. Equity-Insider.com News Commentary  VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This regulatory surge signals deep institutional confidence in late-stage platforms capable of commercial conversion. The trend accelerated in January 2026 as Big Pharma intensified its race to acquire assets ahead of a $170 billion patent cliff[2]. Acquirers are now bypassing early-stage speculation to secure validated Phase 3 data and manufacturing infrastructure. This structural shift has directed institutional focus toward Oncolytic

    1/30/26 10:36:00 AM ET
    $ABBV
    $ADCT
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

    STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on its cash burn rate and financing strategy. The Company's ATM financing vehicle allows the Company to sell its common stock directly into the trading market at market price. The amount raised through our ATM for 2025 exceeded the Company's 2025 cash burn rate of approximately $9.5 million, leading to a year end cash balance of approximately $6

    1/27/26 6:00:00 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indonesia Energy to Present at 3rd Annual DealFlow Discovery Conference on January 28, 2026

    President Frank Ingriselli will Provide Update on Two New Wells at Kruh Block, Where Pre-Drilling Operations Have Commenced JAKARTA, INDONESIA AND DANVILLE, CA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indonesia Energy Corporation (NYSE:INDO) ("IEC"), an oil and gas exploration and production company focused on Indonesia, today announced that IEC's President Frank Ingriselli will be making a presentation on January 28, 2026 at the upcoming DealFlow Discovery Conference taking place in Atlantic City, New Jersey, During his presentation, Mr. Ingriselli will provide more updates on IEC's current drilling operations at Kruh Block, as well as other current information about IEC. In addition, a new

    1/26/26 8:00:00 AM ET
    $INDO
    Oil & Gas Production
    Energy

    $CMRA
    $EMBK
    $GLSI
    $HLVX
    SEC Filings

    View All

    SEC Form 424B5 filed by Indonesia Energy Corporation Limited

    424B5 - Indonesia Energy Corp Ltd (0001757840) (Filer)

    2/5/26 4:08:40 PM ET
    $INDO
    Oil & Gas Production
    Energy

    Hour Loop Inc. filed SEC Form 8-K: Leadership Update

    8-K - Hour Loop, Inc (0001874875) (Filer)

    2/3/26 9:00:30 AM ET
    $HOUR
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 6-K filed by Indonesia Energy Corporation Limited

    6-K - Indonesia Energy Corp Ltd (0001757840) (Filer)

    1/2/26 4:05:14 PM ET
    $INDO
    Oil & Gas Production
    Energy

    $CMRA
    $EMBK
    $GLSI
    $HLVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and CFO Patel Snehal bought $53,694 worth of shares (1,800 units at $29.83), increasing direct ownership by 0.03% to 5,604,102 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    1/15/26 6:05:06 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and CFO Patel Snehal bought $79,866 worth of shares (2,900 units at $27.54), increasing direct ownership by 0.05% to 5,602,302 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    1/14/26 6:05:06 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bui Hillary Hui-Chong was granted 1,514 shares, increasing direct ownership by 7% to 21,924 units (SEC Form 4)

    4 - Hour Loop, Inc (0001874875) (Issuer)

    1/7/26 4:05:43 PM ET
    $HOUR
    Catalog/Specialty Distribution
    Consumer Discretionary

    $CMRA
    $EMBK
    $GLSI
    $HLVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Noble Capital Markets initiated coverage on Greenwich LifeSciences with a new price target

    Noble Capital Markets initiated coverage of Greenwich LifeSciences with a rating of Outperform and set a new price target of $45.00

    8/20/25 9:27:20 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HilleVax downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded HilleVax from Outperform to Market Perform and set a new price target of $2.00 from $28.00 previously

    7/9/24 9:48:14 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax downgraded by Stifel with a new price target

    Stifel downgraded HilleVax from Buy to Hold and set a new price target of $3.00 from $34.00 previously

    7/9/24 7:46:22 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMRA
    $EMBK
    $GLSI
    $HLVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and CFO Patel Snehal bought $53,694 worth of shares (1,800 units at $29.83), increasing direct ownership by 0.03% to 5,604,102 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    1/15/26 6:05:06 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and CFO Patel Snehal bought $79,866 worth of shares (2,900 units at $27.54), increasing direct ownership by 0.05% to 5,602,302 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    1/14/26 6:05:06 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and CFO Patel Snehal bought $91,848 worth of shares (4,300 units at $21.36), increasing direct ownership by 0.08% to 5,599,402 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    1/5/26 6:06:39 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMRA
    $EMBK
    $GLSI
    $HLVX
    Leadership Updates

    Live Leadership Updates

    View All

    Frazier Life Sciences Appoints Aditya Kohli to Partner

    Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

    4/17/25 8:00:00 AM ET
    $HLVX
    $PHAT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

    Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "We are excited to remain on track to r

    5/9/24 4:05:00 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

    BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr. McLoughlin's appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy.  Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Le

    1/18/24 7:00:00 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMRA
    $EMBK
    $GLSI
    $HLVX
    Financials

    Live finance-specific insights

    View All

    HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

    BOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today they have entered into a definitive merger agreement (the "Merger Agreement"), whereby XOMA Royalty will acquire all of the issued and outstanding common shares of HilleVax.   Under the terms of the Merger Agreement, HilleVax stockholders will receive $1.95 in cash per share of HilleVax common stock at the closing of the merger, plus one non-transferable contingent value right ("CVR"), which represents the right to receive potential payments following the closing of a pro rata portion of:

    8/4/25 7:00:00 AM ET
    $HLVX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Indonesia Energy Webinar Interactive Conference Call to be held Today, January 21 at 10AM Eastern Time.

    Company to Provide Update on Production, Future Drilling and Development Plans, Including a Planned New Reserve Report and its New Corporate Logo and Investor Relations Outreach JAKARTA, INDONESIA AND DANVILLE, CA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Indonesia Energy Corporation (NYSE:INDO) ("IEC"), an oil and gas exploration and production company focused on Indonesia, today announced that IEC senior management will hold an investor update conference call today, Tuesday, January 21 at 10:00 AM Eastern Time to provide an update on production, future drilling and development plans, including a new planned reserve report and the unveiling of IEC's new corporate logo and investor relations out

    1/21/25 7:00:00 AM ET
    $INDO
    Oil & Gas Production
    Energy

    Indonesia Energy to Hold Investor Conference Call to Provide Update on Future Drilling and Development Plans, Including a Planned New Reserve Report and its New Corporate Logo and Investor Relations Outreach

    Estimated Ultimate Recovery (EUR) increase of 30% in Kruh Field Webinar Media Interactive Call will be Held on Tuesday, January 21 at 10AM Eastern Time JAKARTA, INDONESIA AND DANVILLE, CA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Indonesia Energy Corporation (NYSE:INDO) ("IEC"), an oil and gas exploration and production company focused on Indonesia, today announced that IEC senior management will hold an investor update conference call on Tuesday, January 21 at 10:00 a.m. Eastern Time to provide an update on future drilling and development plans, including a new planned reserve report and the unveiling of IEC's new corporate logo and investor relations outreach program. As a result of the 3-D

    1/14/25 8:00:00 AM ET
    $INDO
    Oil & Gas Production
    Energy

    $CMRA
    $EMBK
    $GLSI
    $HLVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

    SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

    11/14/24 9:36:33 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

    SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

    11/14/24 9:00:08 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by HilleVax Inc.

    SC 13G - HilleVax, Inc. (0001888012) (Subject)

    7/22/24 9:02:05 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care